Lin Yun-Ting, Lu Jeng-Wei, Ho Yi-Jung, Lui Shan-Wen, Hsieh Ting-Yu, Wang Kuang-Yih, Liu Feng-Cheng
Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, R.O.C.
Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
In Vivo. 2025 Jan-Feb;39(1):572-576. doi: 10.21873/invivo.13862.
BACKGROUND/AIM: Hydrogen therapy has demonstrated potential as an antioxidant and anti-inflammatory intervention, particularly in the management of chronic diseases such as chronic kidney disease (CKD) and autoimmune conditions. This case report presents the possible therapeutic benefits of molecular hydrogen capsule treatment in enhancing renal function and alleviating chronic fatigue in an elderly female with coronary artery disease (CAD), type 2 diabetes mellitus (DM) complicated by nephropathy, and systemic lupus erythematosus (SLE). The aim of this study was to investigate the efficacy of adjunctive hydrogen therapy in an elderly patient with multiple chronic comorbidities.
An 89-year-old female with a history of CAD s/p who had undergone coronary artery bypass grafting (CABG) over 40 years ago, type 2 DM complicated by nephropathy, and SLE was admitted with recurrent cellulitis at the saphenous vein donor site from her previous CABG. Despite antibiotic treatment, wound healing remained limited. In January 2023, the patient initiated adjuvant treatment with molecular hydrogen capsules. Following the introduction of hydrogen therapy, her renal function improved, evidenced by a reduction in serum creatinine levels. Chronic fatigue, assessed using the Taiwan Brief Fatigue Inventory (BFI-T), showed significant improvement. Immunological evaluation revealed a series of changes, suggesting that immune modulation may be the mechanism underlying the observed clinical benefits.
Hydrogen therapy was associated with improved renal function and a reduced chronic fatigue in this elderly patient with multiple comorbidities, including CAD, DM, and SLE. The case underscores the potential therapeutic role of hydrogen therapy in immune modulation and the management of chronic conditions, suggesting the need for further investigation in clinical settings.
背景/目的:氢疗法已显示出作为抗氧化和抗炎干预手段的潜力,特别是在慢性疾病如慢性肾脏病(CKD)和自身免疫性疾病的管理中。本病例报告展示了分子氢胶囊治疗在改善一名患有冠状动脉疾病(CAD)、2型糖尿病(DM)合并肾病以及系统性红斑狼疮(SLE)的老年女性的肾功能和缓解慢性疲劳方面可能具有的治疗益处。本研究的目的是调查辅助氢疗法在一名患有多种慢性合并症的老年患者中的疗效。
一名89岁女性,有CAD病史,40多年前接受过冠状动脉旁路移植术(CABG),患有2型DM合并肾病以及SLE,因先前CABG时隐静脉供体部位反复出现蜂窝织炎入院。尽管进行了抗生素治疗,伤口愈合仍然有限。2023年1月,患者开始使用分子氢胶囊进行辅助治疗。引入氢疗法后,她的肾功能得到改善,血清肌酐水平降低证明了这一点。使用台湾简明疲劳量表(BFI-T)评估的慢性疲劳有显著改善。免疫学评估显示出一系列变化,表明免疫调节可能是观察到的临床益处的潜在机制。
氢疗法与该患有多种合并症(包括CAD、DM和SLE)的老年患者肾功能改善和慢性疲劳减轻相关。该病例强调了氢疗法在免疫调节和慢性病管理中的潜在治疗作用,表明需要在临床环境中进行进一步研究。